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Abstract: Von Willebrand disease (vWD) is the most common hereditary bleeding   disorder. 
The aim of therapy is to correct the dual hemostatic defect, due to defective platelet adhesion-
aggregation and abnormal coagulation due to Factor VIII (FVIII) deficiency. The choice of 
treatment depends on a number of factors, including the severity of the bleed, the procedure 
planned, the subtype and severity of the disease and the age and morbidity of the patient. 
  Desmopressin (DDAVP) is the treatment of choice for type 1 vWD as it increases endogenous 
release of FVIII and von Willebrand factor (vWF) and is also used in some subtypes of type 2 
vWD. In those patients in whom DDAVP is ineffective or contraindicated, levels can be restored 
by infusing vWF:FVIII concentrates. The role of antifibrinolytic treatment is an important 
adjunct to replacement therapy during minor or major surgery involving mucosal surfaces. 
The dosing and timing of vWF:FVIII concentrates is important depending on the nature of 
the surgical procedure. The role of secondary prophylaxis needs to be further defined.
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Introduction
Von Willebrand disease (vWD) is the commonest congenital bleeding disorder, with 
a prevalence estimated from population studies of about 1%.1 It is caused by inherited 
defects in the concentration, structure or function of von Willebrand factor (vWF). 
vWF has two essential functions:
•	 Primary hemostasis – vWF enables platelets to adhere to injured vascular 
  endothelium and then to form platelet aggregates.
•	 Secondary hemostasis – vWF binds to and stabilizes factor VIII (FVIII). In the pres-
ence of vWF the half-life of FVIII is 8–12 hours, in its absence it is ,1 hour.
The vWF gene is located on the short arm of chromosome 12 (12p13.2).2   Mutations 
in the vWD gene result in quantitative or qualitative defects of vWF. The current clas-
sification of vWD is as follows:3,4 
Quantitative defects:
•	 Type 1 vWD – partial loss of vWF
•	 Type 3 vWD – total loss of vWF
Qualitative: type 2 vWD defects:
•	 Type 2A – absence of high molecular weight (HMW) multimers of vWF
•	 Type 2B – increased affinity of vWF for platelet glycoprotein Ib (GpIb), 
causing removal of HMW multimers from plasma and associated with 
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•	 Type 2M – defective interaction between vWF and 
  platelets and no loss of HMW multimers
•	 Type 2N – defect in the N-terminal region of vWF 
where the binding domain for FVIII is located resulting 
in reduced binding of vWF to FVIII. No loss of HMW 
multimers.
The aim of therapy in vWD is to correct the dual hemo-
static defect, due to defective platelet adhesion-aggregation 
and abnormal coagulation due to FVIII deficiency. These 
deficiencies can be corrected by increasing endogenous 
production of FVIII and vWF function using desmopressin 
(DDAVP®) or by administration of vWF concentrates. The 
choice of treatment depends on a number of factors including 
the nature of the bleed or invasive procedure planned, the sub-
type and severity of vWD, the duration of treatment, the age 
of the patient and the previous response to treatment. Other 
treatments, such as antifibrinolytic agents (eg, tranexamic 
acid), can be used alone or as an adjunctive treatment, in order 
to achieve a hemostatic effect, without affecting the vWF 
levels. This review summarizes our management of patients 
with vWD based on the literature and our experience.
Desmopressin
Desmopressin (1-desamino-8-D-arginine vasopressin, 
DDAVP), a synthetic vasopressin analog, increases endog-
enous vWF by secreting it from its natural site of synthesis 
and storage, the vascular endothelial cell.5 It can be adminis-
tered intravenously,6,7 subcutaneously8 or intranasally.7 The 
intravenous dose is 0.3 mcg/kg (maximum dose 28 mcg), 
given diluted in normal saline over 30 minutes. Treatment 
can be repeated every 12–24 hours depending on the type or 
severity of the bleed. Plasma vWF:FVIII levels are increased 
to 2–4 times above the baseline within 30 minutes and in 
general high levels last in the plasma for 6–8 hours.11,12
DDAVP is a very valuable drug as it avoids exposure 
to blood products and is a cheaper alternative. The vWD 
subtype, however affects the decision on whether to use 
DDAVP or a vWF- containing concentrate. It has been used 
cautiously in children because of the risk of hyponatremic 
seizures, although this risk must be balanced against that of 
exposing a child to a pooled blood product.9
DDAVP is usually effective in patients with type 1 vWD 
and baseline vWF and FVIII levels higher than 10 IU/dL.10 
In order to assess the response to DDAVP, a trial should be 
performed, measuring the FVIII and vWF ristocetin   cofactor 
(vWF:RCo) pre-infusion and 1 hour post-infusion. An 
additional assay can be performed at 2–4 hours to evaluate 
for shortened survival of vWF, and should be considered in 
patients with a poor response to treatment.11 In a prospective 
trial   conducted by Castaman et al, complete responses 
(post-infusion levels of FVIII:C and vWF:RCo of at least 
50 IU/dL) or partial responses (post-infusion levels of FVIII:C 
and vWF:RCo less than 50 IU/dL, but at least 3-fold the 
basal   levels) were observed in 84% and 13% of the cases, 
  respectively. This was reduced in other sub-types of vWD.12
By performing half-life studies, patients with acceler-
ated clearance of vWF and FVIII can be identified, such 
as those with Vicenza type vWD. This variant of vWD is 
due to a specific mutation, Arg1205His, which promotes 
increased clearance of vWF from the circulation (five times 
more rapidly than normal). This information could therefore 
influence treatment.13
The response to DDAVP is variable in types 2A and 2M 
and a therapeutic trial is indicated to assess the response 
of vWF:RCo and FVIII.14,15 Its use in type 2B is contro-
versial, as the release of abnormal vWF multimers with an 
increased affinity for glycoprotein Ib leads to the transient 
appearance of thrombocytopenia, but there are a few reports 
where it has been used safely.16,17 DDAVP increases FVIII 
in Type 2N vWD in most patients but the half-life is signifi-
cantly reduced,18 therefore it is usually used in minor bleeding 
episodes, and vWF concentrate should be used to treat major 
bleeding or for invasive procedures.
DDAVP does not have any therapeutic use in type 3 vWD, 
and these patients must be treated with a vWF-containing 
concentrate.
The main limitation of using DDAVP is the development 
of tachyphylaxis, ie, the progressive reduction of responsive-
ness after repeated treatments.19 Hyponatremia, volume over-
load and subsequent seizures can be associated with DDAVP, 
due to repeated dosing within short intervals, therefore fluid 
restriction and serum sodium monitoring are advisable.20 As 
there have been reports of myocardial infarction and stroke 
in elderly patients with established atherosclerotic disease, 
DDAVP should be used cautiously in such patients.21,22
von Willebrand factor-containing 
concentrate
For those patients in whom DDAVP is ineffective or 
  contraindicated, vWF and FVIII levels can be restored by 
infusion of concentrates, which may contain both FVIII and 
vWF or very high-purity vWF with minimum or no FVIII.30 
When considering a vWF containing concentrate, there are 
minimal requirements: these products must have the same 
level of safety in eliminating the potential of blood-borne 
infections, and contain vWF that promotes adhesion and Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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aggregation of platelets as well as transport and stabilization 
of FVIII.23 The pharmacokinetics and the efficacy of these 
products should be tested in patients with different types of 
vWD and be labeled with both vWF and FVIII potency.24
As vWF is a plasma-derived product, the risk of viral 
transmission has been minimized through the development 
of procedures for the viral inactivation of the plasma-derived 
concentrate. There is growing concern regarding the trans-
mission of variant Creutzfeld Jacob Disease (vCJD) through 
blood products. In the UK there have been 4 cases of infection 
transmitted by blood transfusions from individuals who later 
developed vCJD25 and one case of a hemophilic who died 
of unrelated causes, but was found to have the vCJD prion 
protein in his spleen at post mortem.26 These concerns are 
fuelling the demand for alternative treatment options such 
as recombinant vWF.
Important progress has been made in the standardization of 
vWF measurements in both plasma samples and concentrates 
which has been facilitated through the calibration of the WHO 
first International Standard for vWF:Ag and vWF:RCo.27
Studies demonstrate the hemostatic efficacy of a number 
of vWF-containing concentrates in the clinical settings of 
acute bleeds and surgical procedures, but there is no data to 
support the view that any concentrate has superior efficacy 
to any other. Commonly used products and their pharma-
cokinetic properties are shown in Table 1.28–36
The amount of vWF-containing concentrate required to 
correct the hemostatic defect in vWD is dependent on the 
nature of a bleed, a patient’s baseline vWF:RCo and FVIII and 
their subtype of vWD. In addition different types of surgery 
require different target vWF:RCo and FVIII levels.36
Patients vary in their response to infusions of vWF-
containing concentrate, therefore treatment regimens 
need to be individualized. Knowledge of an individual’s 
pharmacokinetic response to infused vWF-containing 
concentrate is a therapeutic advantage, and the previous 
demonstration of hemostatic efficacy correlates well with 
prospective therapy for surgery or management of acute 
bleeding episodes.37
The vWF:RCo and FVIII levels required for hemostasis 
have not been established in clinical trials. The general 
consensus however, for major operative procedures or sig-
nificant bleeding, is that the vWF:RCo and FVIII should be 
raised to above 80 IU/dL and maintained above 50 IU/dL 
until hemostasis is secured and the FVIII level should be 
maintained above 50 IU/dL until wound healing is complete. 
Minor surgery may be performed successfully with a vWF: 
RCo and FVIII of approximately 50 IU/dL.35,41–43
Sustained high levels of FVIII may increase the risk of 
venous thrombosis,38–40 therefore when repeated infusions 
of vWF:FVIII concentrates are necessary (eg, surgical 
procedures), the FVIII:C plasma levels should be measured 
daily to avoid levels in excess of 150 IU/dL.40 As vWF:RCo 
has a half life of 8–10 hours, and FVIII:C a half-life of 
24–26 hours, both these levels should be monitored during 
prolonged treatment. Mannuci et al41 recommend primary 
thromboprophylaxis in vWD patients undergoing replace-
ment therapy for major surgery and procedures at high risk 
of venous thromboembolism, at the same dosing schedules 
as for non-vWD patients.
All patients with vWD produce FVIII. In order to avoid 
excessively high FVIII levels after infusing vWF concen-
trates, a highly purified vWF (HP-vWF) concentrate con-
taining very little FVIII has been developed. This differs 
from other vWF concentrates as the post-infusion levels of 
FVIII rise slowly, reaching a peak 6–12 hours post-infusion. 
Combined data from a number of trials for a HP-vWF con-
centrate (Wilfactin) has shown that clinical outcomes were 
excellent or good in 89% of patients with spontaneous bleeds, 
although 38% of cases needed concomitant FVIII. Excellent 
or good efficacy was also observed in 95 elective surgical 
procedures without the need for prophylactic therapy with 
FVIII; however FVIII concentrate was required in 13 other 
patients needing surgery.42
A HP-vWF concentrate could potentially be utilized 
when prolonged infusion of product is needed, such as major 
elective surgery in those patients who are at a higher risk of 
developing thrombosis (old age, cancer, orthopedic surgery). 
Further studies are needed to identify the most appropriate 
patients and indications for use.
Adjunctive treatments
Management of mucosal bleeding, menorrhagia or prolonged 
oral bleeding after dental extraction involves the adminis-
tration of antifibrinolytic amino acids (eg, tranexamic acid, 
epilson aminocapric acid). These agents inhibit the conver-
sion of plasminogen to plasmin, inhibiting fibrinolysis and 
thereby helping to stabilize clots that have been formed. They 
can be administered either intravenously or orally, and can 
be used alone or as an adjunct to replacement therapy, to 
prevent or treat bleeding in mucosal tracts characterized by 
a rich fibrinolytic activity.44
These agents are also useful in administration along 
with replacement therapy during minor or major surgery 
involving mucosal surfaces.44 Tranexamic acid should be 
administered at a dose of 15–25 mg/kg orally (or 0.5–1 g Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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intravenously [IV]) every 8–12 hours and aminocaproic 
acid at a dose of 50–60 mg every 4–6 hours. These drugs are 
contraindicated in the management of urinary tract bleeding, 
due to the increased risk of intra-renal obstruction due to clot 
retention, in the renal pelvis or ureters.45
Topical Bovine thrombin or Fibrin sealant can be used 
as adjuncts to hemostasis in certain surgical situations espe-
cially in dental procedures.46 They are not useful in massive 
hemorrhage. Topical collagen sponges are also of use for the 
control of bleeding wounds.47
Platelets contain 10%–15% of total blood vWF, and 
platelet transfusions have been used successfully to treat 
bleeding in patients with vWD.48 Platelet transfusion should 
be considered in patients with type 3 or platelet-low vWD to 
control bleeding that is not responsive or poorly responsive 
to replacement therapy with vWF concentrate.
Management of specific  
bleeding problems
Dental treatment
Treatment with DDAVP or concentrate is unnecessary for 
fillings performed under infiltration with local anesthetic; 
however treatment should be given if an inferior dental nerve 
block is used.35 In patients unsuitable for DDAVP, vWF-
containing concentrate should be used, aiming to increase 
the vWF:RCo and FVIII to .50 IU/dL.41 Oral antifibrinolytic 
agents should be commenced before treatment (along with 
local measures such as antifibrinolytic mouthwash) and 
continued for 7–10 days following extraction.
Bleeding in women
As mucocutaneous bleeding is the most common phenotype 
of bleeding in vWD, females with this disorder are fre-
quently affected by reproductive tract bleeding and related 
complications.49
Gynecological disorders
Menorrhagia is common in women with vWD, affecting 
an estimated 80%–90% of patients.50 It may however, be 
a symptom of an underlying gynecological disorder,51 
therefore it should be fully investigated. A study on behalf 
of the International Society of Thrombosis and Hemostasis 
(ISTH), demonstrated that up to a quarter of women required 
a hysterectomy for menorrhagia.52 Therefore, both medical 
and surgical treatments should be considered.
Both ovarian cysts and endometriosis occur more fre-
quently in women with vWD compared with their normal 
counterparts.53 It is hypothesized that endometriosis is caused 
by retrograde menstruation and that vWD exacerbates and 
‘unmasks’ this condition.
Medical therapies that have been used to control bleed-
ing in vWD are the combined oral contraceptive pill (OCP), 
tranexamic acid, DDAVP and the levonorgesterel-releasing 
intrauterine system.54 In females who don’t want to become 
pregnant, but who wish to have children in the future, the 
first choice of therapy should be the OCP (containing syn-
thetic estrogen and a progestin).55 The progestin prevents 
ovulation and the synthetic estrogen prevents breakthrough 
bleeding.56 Studies have found that the OCP can increase 
levels of fibrinogen, FVIII and vWF.57–59
Intrauterine devices, such as the levonorgesterel-releasing 
intrauterine devices can be used as an alternative therapy in 
suitable candidates. This system is a progestin impregnated 
device, which is believed to reduce menstrual blood loss by 
opposing the estrogen induced growth of the endometrium.60
Alternative treatments in addition to medical therapy 
may have to be considered in difficult cases. This involves 
therapies such as endometrial ablation which has been proven 
to help control bleeding in women with vWD.61
Pregnancy
In normal pregnancy there is a progressive increase in FVIII 
and vWF levels from the second trimester onwards.62 This 
also occurs in women with vWD, which may explain the 
frequent improvement in minor bleeding manifestations 
during pregnancy.63–65
Most women with type 1 vWD have a progressive 
increase in vWF and FVIII, which may make the diagnosis 
difficult during pregnancy.66,67
In type 2 vWD, FVIII and vWF levels increase, but most 
studies show minimal or no increase in vWF activity levels 
and a persistently abnormal pattern of multimers reflecting 
the production of abnormal vWF.50,64,66,68 Most patients with 
type 3 vWD have no improvement in FVIII or vWF levels 
during pregnancy.
Theoretical concerns have been raised regarding the 
use of DDAVP in pregnancy due to the potential risks of 
placental insufficiency (as a result of vasoconstriction), an 
oxytocic effect and maternal and/or neonatal hyponatremia.69 
No adverse effects were noted in association with DDAVP 
given in the second trimester in 32 women with vWD who 
underwent chorionic villous sampling or amniocentesis.70 
Similarly, a systemic review of DDAVP in pregnant women 
with diabetes insipidus found no evidence of uterine stimula-
tion, prematurity or low birth weight associated with the use 
of DDAVP antepartum.71Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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The vWF:RCo and FVIII levels for pregnant women 
with vWD should be measured at least once during the third 
trimester of pregnancy and within 10 days of the expected 
date of delivery.74 The risk of bleeding is minimal if FVIII and 
vWF:RCo are greater than 30 IU/dL. These levels should also 
be measured for at least 2 weeks post-partum. The rapid fall-
off in vWF and FVIII levels that occurs post-partum, means 
that women are at an increased risk of post-partum hemor-
rhage (PPH), which is higher in type 2 and 3 disease and 
can persist for 7–21 days after delivery.73 A study from the 
Centers for Disease Control found that 59% of women with 
vWD experience a PPH compared with 21% of controls.60
Epidural anesthesia for pain relief may be considered 
with caution in patients with type I vWD, as the majority will 
have levels which have risen to within the normal range dur-
ing pregnancy.42 Each individual patient’s risk of bleeding, 
however, should be considered, depending on the degree of 
correction of FVIII and vWF level, and the anesthetist and 
obstetrician should be consulted. Epidural anesthesia is not 
recommended in type 2 and 3 vWD.42
In type 1 vWD, if the levels are lower than 30 IU/dL it may 
be necessary to administer DDAVP, which may be necessary 
for procedures during pregnancy or at the time of delivery.
In Type 2 and Type 3 vWD observation alone without 
treatment is sufficient if the FVIII . 50 IU/dL. Dosing 
at delivery is usually 40–80 IU/kg vWF-concentrate and 
  prophylaxis has usually been targeted to maintain vWF:RCO 
and FVIII . 50 IU/dL for at least 3–5 days postpartum.72
When the fetus is at risk of having type 2 or 3 vWD, 
invasive measures such as fetal scalp monitoring, rota-
tional forceps, or ventouse delivery should be avoided.42 
Irrespective of the mode of delivery, newborns at risk of type 
2 or 3 vWD need to be tested for vWD using cord blood sam-
pling and assessed to rule out an intra-cranial hemorrhage; 
early replacement therapy may be required depending on the 
nature of the delivery. Cord blood screening for type 1 vWD 
will not give reliable results.42
In type 2B vWD, increased production of mutant vWF 
may result in spontaneous platelet aggregation and severe 
thrombocytopenia during the third trimester. Platelet transfu-
sion may therefore be required at delivery.48
Acute bleeding
For severe spontaneous or trauma-induced bleeding the vWF: 
RCo and FVIII levels should be increased to approximately 
80 IU/dL, until bleeding has been controlled. Adjunctive 
treatment, such as antifibrinolytic drugs and other local 
  measures to achieve hemostasis should be considered, 
  especially in mucosal bleeding. Lower levels of vWF:RCo 
and factor VIII are sufficient for minor bleeds.
vwD and surgical procedures
Patients with vWD undergoing surgical procedures, need 
regular assessment and correction of hemostasis pre and 
post-operatively. It is important to recognize that abnormal 
bleeding can be as a result of surgical bleeding, rather than 
inadequate hemostasis. The different subtypes of vWD 
have different product requirements, which are shown in 
Table 2.
A vWF:RCo and FVIII of 50 IU/dL should be adequate 
for minor procedures, and often only one infusion is required. 
Antifibrinolytics can be administered both pre and post 
operatively to assist with hemostasis.
An infusion of a vWF- concentrate calculated to increase 
the vWF:RCo level to 80–100 IU/dL at the time of surgery 
is recommended and this level should be maintained above 
50 IU/dL until hemostasis is secure.35,41 The FVIII should be 
raised to approximately 100 IU/dL perioperatively and main-
tained above 50 IU/dL until wound healing is complete. This 
requires regular monitoring of both vWF:RCo and FVIII.
HP-vWF concentrates are infused at a dose of 50 IU/kg 
vWF:RCo, 12–24 hours before surgery if the FVIII is less 
than 60 IU/dL. A further dose is given 1 hour before surgery 
and subsequent infusions are given to maintain a vWF:RCo 
level . 60 IU/dL and a FVIII level . 40 IU/dL. Unscheduled 
surgery is treated with HP-vWF concentrate at 50 IU/kg and 
FVIII to the same target levels.72
The risk of VTE should be assessed in patients undergo-
ing major surgery, who receive vWF-containing concen-
trates, and therefore high levels of FVIII should be avoided, 
and thromboprophylaxis considered.41
A summary of the initial dosing recommendations for 
vWF concentrate replacement for prevention or management 
of bleeding is shown in Table 3.49
Table 2 Product types required, depending on sub-type of vwD, 
in minor and major surgical procedures
vWD 
subtype
Minor surgical 
procedures treatment
Major surgical 
procedure treatment
Type 1 DDAvP vwF concentrate
Type 2A/2M DDAvP vwF concentrate
Type 2B vwF concentrate vwF concentrate
Type 2N DDAvP vwF concentrate
Type 3 vwF concentrate vwF concentrate
Note: Antifibrinolytic therapy, both pre and post-operatively (until wound healing 
achieved) should be used as an adjunct in both minor and major surgical procedures.
Abbreviations:  DDAvP,  desmopressin  (1-desamino-8-D-arginine  vasopressin); 
vwF, von willebrand Factor; vwD, von willebrand Disease. Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Prophylaxis
The most prominent symptom in vWD is that of mucosal 
bleeding (eg, epistaxis, gastrointestinal bleeding and 
  menorrhagia). Hemarthrosis (joint bleeding), and spontane-
ous muscular bleeding, resembling those of hemophilia, 
may occur rarely, particularly in patients with a secondary 
deficiency of FVIII. It has been reported, in some series that 
37%–45% of subjects with type 3 vWD had experienced at 
least one episode of hemarthrosis.73,74
The first data on the usefulness of prophylaxis was 
obtained from Sweden, where retrospective data from 
35 patients demonstrated that vWF/FVIII infusions admin-
istered at least once weekly were found to substantially 
reduce mucosal bleeding and hemarthrosis and there was no 
evidence of progression to arthropathy.75 There is a potential 
role for prophylaxis in vWD.
According to a survey of 74 centers in Europe and North 
America approximately three-quarters of patients receiving 
prophylaxis have type 3 vWD. Indications for prophylaxis 
include recurrent hemarthrosis (14%), epistaxis (23%), gas-
trointestinal bleeding (14%), and menorrhagia (5%).76
The optimum prophylactic regimen for vWD has not yet 
been established, and it is likely that it may not need to be 
administered as regularly as prophylaxis for patients with 
severe hemophilia A. Retrospective data from 120 patients 
enrolled on an Italian national registry has suggested that 
long-term secondary prophylaxis with vWF/FVIII (40 IU/kg) 
prevents or reduces bleeding in vWD patients with a his-
tory of recurrent hemorrhage.77 There is now a prospective 
randomized study comparing on-demand and prophylactic 
treatment, and the results of these studies will help better 
define the role of prophylaxis in patients with von Willebrand 
disease, and also provide more data on the optimum   treatment 
regimes.
The future
The management of vWD has changed over the past 15 years, 
and treatments such as DDAVP, vWF containing concentrate 
are well established. The role of secondary prophylaxis needs 
to be further defined. The development of recombinant vWF 
currently undergoing phase 1 studies in type 3 vWD is likely 
to offer further treatment options in the future.78 Alternative 
therapy such as gene therapy, which is attempting to partially 
correct vWF defects, may change management in the future 
in patients with type 3 vWD.49
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